This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Opioid Analgesics Market

Market Insights on Opioid Analgesics covering sales outlook, demand forecast & up-to-date key trends

Opioid Analgesics Market by Drug Class (Morphine, Codeine, Fentanyl, Meperidine, Methadone, Tramadol, Oxycodone, Dextromethorphan, Buprenorphine, Others), Indication (Surgical Pain, Cancer Pain), Route of Administration (Oral, Parenteral, Transdermal, Other), End User & Region - Forecast to 2021 - 2031

Opioid Analgesics Market Snapshot

[315 Pages Report] As per a recent market analysis by Future Market Insights (FMI), demand in the Opioid Analgesics Market is slated to increase at a 5.4% CAGR, reaching a valuation of US$ 39.0 Bn in 2021.

Rising demand for post-surgery pain management and improvements in drug formulations to reduce side effects of analgesics are expected to continue driving sales of Opioid Analgesics over the forecast period.

Sales of morphine are anticipated to command 13% of the overall Opioid Analgesics Market share, and the market valuation is projected to total US$ 65.8 Bn in 2031, opines FMI.

Opioid Analgesics Market Outlook

Data Points

Market Insights

Market Value 2020

USD 37.05 Bn

Market Value 2021

USD 38.97 Bn

CAGR 2021-2031

5.4%

Key Players

The key players in Opioid Analgesics market are Pfizer Inc, Abbott Laboratories, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Bayer AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., and Sanofi S.A. 

Customize this Report

Let us know your requirement to get
100% FREE customization

Key Points Covered in Opioid Analgesics Market Survey

  • Opioid Analgesics Market estimates and forecast 2021-2031
  • Key drivers and restraints impacting market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Brand share and Opioid Analgesics Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Opioid Analgesics and how to Navigate
  • Recommendation on Key Winning Strategies

Opioid Analgesics Historic Sales Compared to 2021-2031 Forecast Outlook

Demand for opioid analgesics grew at a steady pace, exhibiting a 4.2% CAGR between 2016 and 2020. As per the report, oxycodone had the highest Opioid Analgesics Market share, capturing 19.7% of the total sales recorded in 2020.

Increasing incidence of chronic pain & orthopaedic diseases among the geriatric population is fuelling growth of the opioid analgesics market. Also, rising disposable income and increasing expenditure on healthcare are some factors anticipated to boost growth of the Opioid Analgesics Market during the forecast period.

Opioid Analgesics Market Download Report Brochure

Opioids are known to be the most effective drugs for pain management. Their utilization in chronic pain management is a standard procedure in many countries across the world.

In response to growing incidence of cancer, orthopaedic diseases and neuropathic pain, demand for opioid analgesics is predicted to grow at a steady pace. FMI has projected the Opioid Analgesics Market to expand at a 5.4% CAGR through 2031.

What are Key Opportunities for Opioid Analgesics Manufacturers?

The convenience and efficacy of opioid analgesics makes them the most preferred drugs for pain management and palliative care. However, to eliminate chances of addiction and overuse, certain regulations are imposed on sales of opioids.

As a result, manufacturers are trying to improve their product offerings by investing in research and development to develop milder and less addictive drugs. This is indicative of lucrative growth opportunities for key opioid analgesics manufacturers.

On the flipside, many people find smaller doses of opioids to be ineffective in treating severe pain. These patients need to take a higher dose of drugs to subdue their pain, which eventually makes them opioid tolerant, and in some cases, addicted to these drugs.

Hence, commercializing opioid-tolerant drugs is anticipated to be one of the main opportunities for manufacturers in the opioid drugs market. This will also help in decreasing the side effects caused by or associated with high consumption of opioid drugs, which in turn, will boost sales of opioid analgesics over the forthcoming years.

How COVID-19 has Impacted Opioid Analgesics Market?

The COVID-19 pandemic has had a negative impact across the medical sector, such as reduction in face-to-face appointments and a rise in telehealth visits. Lockdown restrictions were imposed to control the virus and sustain sufficient capacity in hospitals.

Chronic pain remained one of the toughest-hit fields from the COVID-19 pandemic, leaving most of patients with their ongoing treatment delayed and sustained with their chronic pain.

For example, as per the research article published in 2020, in the Indian Journal of Anesthesia, by Rajendra K Sahoo et a., the study outcomes found that 63.16% of pain doctors had a fear of contracting or spreading the disease to patient families, 1.43% physicians were suffering from depression, 26.79% had impaired sleep, and 8.14% had feelings of anxiety.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Will Increasing Incidence of Opioid Addiction Hinder Sales?

Unavailability of opioids in emerging economies and side effects associated with these drugs are primary factors restraining growth of the opioid analgesics market. Besides this, increasing severity of abusive opioids and their misuse is another major factor hampering growth of the Opioid Analgesics Market.

In addition to this, chronic side effects associated with opioids pose a major challenge for the growth of the Opioid Analgesics Market. For instance, high consumption of morphine can result in severe issue sin the respiratory system, which sometimes can even lead to coma and eventually death. Long-term usage of morphine can result in psychological and physical addiction and could impair the body’s immune system.

Due to increasing misuse of abusive opioids, physicians have reduced their prescription for pain management, which has reduced their overall sale globally. As per the IASP (International Association for the Study of Pain), about 20–30% of opioids given for chronic pain are being misused. In addition to this, around 10% of the total opioid customers are addicted to it.

Rising incidence of opioid abuse is expected to hinder growth of the opioid analgesics market, as physicians are reluctant to prescribe opioids as a pain medication.

Country-wise Insights

What Makes the U.S. an Attractive Opioid Analgesics Market?

The U.S. is projected to dominate the North America opioid analgesics market, holding 86% of the total market share in 2021. Rising prevalence of chronic illnesses and growing consumption of opioids as a pain medication are expected to continue providing tailwinds to sales of opioid analgesics.

Key manufacturers of opioid analgesics in the U.S. are focusing on launching new products to comply with updated regulatory procedures. In addition to this, support from the government-led investments in clinical research will enable the country to continue its dominance over the forecast period.

What will be the Demand Outlook for Opioid Analgesics in Germany?

Sales of opioid analgesics in Germany are projected to rise at a 3.8% CAGR, reaching a valuation of US$ 2.2 Bn in 2021.

Adoption of opioids maintenance treatment (OMT) for treatment of opioids dependence (OD), increasing utilization of non-abusive opioids, and favourable reimbursement programmes offered by German regulatory bodies concerning awareness of palliative care are key factors propelling sales of opioid analgesics in Germany.

Why is Demand for Opioid Analgesics Rising in the U.K.?

The U.K. is projected to lead the Europe opioid analgesics market, with sales growing at a 4.7% CAGR over the forecast period.

The U.K. healthcare system is a well-renowned and universal system, receiving high funding from the government. It is known to be one of the most flourishing and successful healthcare systems among all the countries.

As per our analysis, the U.K. is recognized as the third-dominating Opioid Analgesics Market, and the position is expected to hold over the forecast period.  Also, the presence of several major players, growing pipeline drugs, and rising research efforts creates a lucrative opportunities for opioids in the U.K.

Why is China Considered an Emerging Market for Opioid Analgesics?

As per FMI, China is anticipated to lead the East Asia market, accounting for 54.2% of the Opioid Analgesics Market share in 2021. China is dominating the East Asia market owing to increasing utilization of high amounts of opioids for pain management and its extensive manufacturing capacity.

China is the second-largest pharmaceutical market in the world due to rapid productivity and large-scale capital investments in the healthcare sector.

How Will Sales of Opioid Analgesics Fare Across India?

India is expected to hold 35.4% of the South Asia opioid analgesics market share in 2021, with sales growing at a steady 5.7% CAGR.

Small and large pharmaceutical companies in India are actively investing in research and development in response to growing demand for opioid analgesics in the country. A large number of novel drugs in the pipeline are almost at the last stage, and will be available to patients soon.

Presence of government-funded medical and pharmaceutical institutions in India are facilitating clinical trials for opioid analgesics. This surge in the research activities in India is expected to propel the growth of the Opioid Analgesics Market in the forthcoming years

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Why is the Demand for Oxycodone Rising?

Based on drug class, oxycodone is projected to account for a dominant Opioid Analgesics Marketshare of 19.4% in 2021.

Oxycodone is one of the most potent pain relievers available in the Opioid Analgesics Market currently. The drug effectively relieves pain and helps patients to continue their daily tasks. Earlier, oxycodone was not adopted due to unawareness of the constituents and high cost of drugs.

However, rising awareness about the advantages of oxycodone such as more bioavailability is supporting the adoption of the drug.

Usage of Opioid Analgesics for Surgical Pain Relief to Continue Rising

In terms of indication, the surgical pain segment is projected to hold 45.9% of the total Opioid Analgesics Market share due to the rising number of surgical procedures and increasing incidence of associated post-operative pain.

Opioid analgesics are utilized as an effective treatment for pain management after operation or surgery. Increasing adoption of medications for managing and reducing pain is anticipated to propel demand for opioid analgesics over the forecast period.

Sales of Opioid Analgesics through Hospital Pharmacies to Gain Momentum

The hospital pharmacies segment is expected to account for 33.1% of the total Opioid Analgesics Market share in 2021.

Hospitals are considered as major care centres with a strong presence of well–trained staff and professionals that assist patients in effective treatment. Adoption of prescribed therapy in clinics and hospitals aids in supervising drug delivery by a physician. This is one of the key factors driving sales of opioid analgesics through hospital pharmacies.

Competitive Landscape

Key players are focusing on expansion in emerging regions and are launching new and revised products to expand their product portfolios. Product approvals, agreements, partnerships, facility expansion, and strategic collaborations are expected to assist Opioid Analgesics Market players in gaining a competitive edge. For instance:

  • In May 2020, Assertio Therapeutics, Inc. merged with Zyla Life Sciences. The merger allowed the companies to expand their product portfolio of neurology, inflammation and chronic pain medications.
  • In September 2021, Bausch Health Companies Inc. and its gastroenterology business, Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data at PAINWeek 2021. RELISTOR® (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

Similarly, recent developments related to companies manufacturing opioid analgesics have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as per Opioid analgesics Industry Analysis

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

US$ Mn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia East Asia, Oceania, and Middle East & Africa

Key Countries Covered

US, Canada, Brazil, Mexico, Germany, U.K., France, Italy, Spain, Benelux, Russia, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Singapore, China, Japan, South Korea, Australia, New Zealand, Turkey, South Africa, and GCC Countries

Key Market Segments Covered

Drug Class, Indication, Route of Administration, Distribution Channel, and Region

Key Companies Profiled

  • Pfizer Inc.
  • Abbott Laboratories
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG,
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Sanofi S.A. 
  • Teva Pharmaceuticals
  • AbbVie Inc. (Allergan plc)
  • Purdue Pharmaceuticals L.P.
  • Sun Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]
  • Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]

Pricing

Available upon Request

Opioid Analgesics Market by Category

By Drug Class:

  • Morphine
  • Codeine
  • Fentanyl
  • Meperidine
  • Methadone
  • Tramadol
  • Oxycodone
  • Dextromethorphan
  • Buprenorphine
  • Others

By Indication:

  • Surgical Pain
  • Cancer Pain
  • Neuropathic Pain
  • Other

By Route of Administration:

  • Oral
  • Parenteral
  • Transdermal
  • Other

By End User:

  • Hospitals
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Frequently Asked Questions

The global opioid analgesics market is anticipated to reach US$ 39.0 Bn in 2021 and is set to expand at 1.7X over the next ten years.

The opioid analgesics market is expected to reach US$ 65.8 Bn by the end of 2031, with sales growing at a 5.4% CAGR.

From 2016-2020, the market for opioid analgesics expanded at a steady 4.2%.

Commercialization of non-abusive opioids, and adoption of opioids maintenance treatment (OMT) to treat opioids dependence (OD), are some of the key trends driving sales of opioid analgesics.

The U.S., Canada, Germany, France, and the U.K. are expected to drive demand for opioid analgesics.

North America is one of the key markets for opioid analgesics, with the U.S. expected to account over 80% of the North America market.

Demand for opioid analgesics in Europe is expected to rise at a steady 5.4% CAGR over the forecast.

The U.S., Germany, the U.K., India, and France are key producers of opioid analgesic.

Japan opioid analgesics market is expected to grow at a 5.6% CAGR, and South Korea is projected to hold 14.5% of the East Asia market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Market Context

    4.1. Drug Adoption / Usage Analysis

    4.2. Key Strategies Adopted By Manufactures

    4.3. Regulatory Scenario

5. Key Inclusion

    5.1. Drug Adoption / Usage Analysis

    5.2. Key Strategies Adopted By Manufactures

    5.3. Regulatory Scenario

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Global Healthcare Outlook

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Increasing Prevalence of Chronic Disease and Surgical Procedures

        6.2.2. Increasing Prevalence of Neuropathic and Chronic pain

        6.2.3. Elevating Awareness about Palliative Care and Pain Management

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

    6.4. Value Chain Analysis

7. COVID19 Crisis Analysis

        7.1.1. Current COVID19 Statistics and Probable Future Impact

        7.1.2. Current GDP Projection and Probable Impact

        7.1.3. Current Economic Projection as compared to 2008 Economic analysis

        7.1.4. COVID19 and Impact Analysis

            7.1.4.1. Revenue By Product

            7.1.4.2. Revenue By Country

8. Global Analgesics Market Demand (in Value or Size in US$ Mn) Analysis 2016-2020 and Forecast, 2021–2031

    8.1. Historical Market Value (US$ Mn) Analysis, 2016-2020

    8.2. Current and Future Market Value (US$ Mn) Projections, 2021–2031

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Absolute $ Opportunity Analysis

9. Global Analgesics Market Analysis 2016-2020 and Forecast 2021–2031, By Drug Class 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2016-2020

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2021–2031

        9.3.1. Morphine

        9.3.2. Codeine

        9.3.3. Fentanyl

        9.3.4. Meperidine

        9.3.5. Methadone

        9.3.6. Tramadol

        9.3.7. Oxycodone

        9.3.8. Dextromethorphan

        9.3.9. Buprenorphine

        9.3.10. Others

10. Global Analgesics Market Analysis 2016-2020 and Forecast 2021–2031, by Indication

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By Indication, 2016-2020

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast Indication, 2021 – 2031

        10.3.1. Surgical Pain

        10.3.2. Cancer Pain

        10.3.3. Neuropathic Pain

        10.3.4. Other 

    10.4. Market Attractiveness Analysis By Indications

11. Global Analgesics Market Analysis 2016-2020 and Forecast 2021–2031, by Route of Administration

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2016-2020

    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast Route of Administration, 2021–2031

        11.3.1. Oral

        11.3.2. Parenteral

        11.3.3. Transdermal

        11.3.4. Others 

    11.4. Market Attractiveness Analysis By Route of Administration

12. Global Analgesics Market Analysis 2016-2020 and Forecast 2021–2031, by Distribution Channel 

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016-2020

    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021–2031

        12.3.1. Hospitals

        12.3.2. Retail Pharmacies

        12.3.3. Drug Stores

        12.3.4. Online Pharmacies

    12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Analgesics Market Analysis 2016-2020 and Forecast 2021–2031, by Region

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2020

    13.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021–2031

        13.3.1. North America

        13.3.2. Latin America

        13.3.3. Europe

        13.3.4. South Asia

        13.3.5. East Asia

        13.3.6. Oceania

        13.3.7. Middle East & Africa

    13.4. Market Attractiveness Analysis By Region

14. North America Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        14.3.1. By Drug Class

        14.3.2. By Indication

        14.3.3. By Route of Administration

        14.3.4. By Distribution Channel

        14.3.5. By Country

            14.3.5.1. U.S.

            14.3.5.2. Canada

    14.4. Market Attractiveness Analysis

    14.5. Drivers and Restraints-Impact Analysis

15. Latin America Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        15.3.1. By Drug Class

        15.3.2. By Indication

        15.3.3. By Route of Administration

        15.3.4. By Distribution Channel

        15.3.5. By Country

            15.3.5.1. Brazil

            15.3.5.2. Mexico

            15.3.5.3. Argentina

            15.3.5.4. Rest of Latin America

    15.4. Market Attractiveness Analysis

    15.5. Drivers and Restraints-Impact Analysis

16. Europe Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        16.3.1. By Drug Class

        16.3.2. By Indication

        16.3.3. By Route of Administration

        16.3.4. By Distribution Channel

        16.3.5. By Country

            16.3.5.1. Germany

            16.3.5.2. Italy

            16.3.5.3. France

            16.3.5.4. U.K.

            16.3.5.5. Spain

            16.3.5.6. BENELUX

            16.3.5.7. Russia

            16.3.5.8. Rest of Europe

    16.4. Market Attractiveness Analysis

    16.5. Drivers and Restraints-Impact Analysis

17. South Asia Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        17.3.1. By Drug Class

        17.3.2. By Indication

        17.3.3. By Route of Administration

        17.3.4. By Distribution Channel

        17.3.5. By Country

            17.3.5.1. India

            17.3.5.2. Thailand

            17.3.5.3. Indonesia

            17.3.5.4. Malaysia

            17.3.5.5. Rest of South Asia

    17.4. Market Attractiveness Analysis

    17.5. Drivers and Restraints-Impact Analysis

18. East Asia Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    18.1. Introduction

    18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        18.3.1. By Drug Class

        18.3.2. By Indication

        18.3.3. By Route of Administration

        18.3.4. By Distribution Channel

        18.3.5. By Country

            18.3.5.1. China

            18.3.5.2. Japan 

            18.3.5.3. South Korea 

    18.4. Market Attractiveness Analysis

    18.5. Drivers and Restraints-Impact Analysis

19. Oceania Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    19.1. Introduction

    19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        19.3.1. By Drug Class

        19.3.2. By Indication

        19.3.3. By Route of Administration

        19.3.4. By Distribution Channel

        19.3.5. By Country

            19.3.5.1. Australia

            19.3.5.2. New Zealand

    19.4. Market Attractiveness Analysis

    19.5. Drivers and Restraints-Impact Analysis

20. Middle East and Africa Analgesics Market Analysis 2016-2020 and Forecast 2021–2031

    20.1. Introduction

    20.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2020

    20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2021–2031

        20.3.1. By Drug Class

        20.3.2. By Indication

        20.3.3. By Route of Administration

        20.3.4. By Distribution Channel

        20.3.5. By Country

            20.3.5.1. GCC Countries

            20.3.5.2. Turkey

            20.3.5.3. Northern Africa

            20.3.5.4. South Africa

            20.3.5.5. Rest of Middle East and Africa

    20.4. Market Attractiveness Analysis

    20.5. Drivers and Restraints-Impact Analysis

21. Key and Emerging Countries Analgesics Market Analysis 

    21.1. Introduction

        21.1.1. Market Value Proportion Analysis, By Key Countries

        21.1.2. Global Vs. Country Growth Comparison

    21.2. U.S. Analgesics Market Analysis

        21.2.1. By Drug Class

        21.2.2. By Indication

        21.2.3. By Route of Administration

        21.2.4. By Distribution Channel

    21.3. Canada Analgesics Market Analysis

        21.3.1. By Drug Class

        21.3.2. By Indication

        21.3.3. By Route of Administration

        21.3.4. By Distribution Channel

    21.4. Mexico Analgesics Market Analysis

        21.4.1. By Drug Class

        21.4.2. By Indication

        21.4.3. By Route of Administration

        21.4.4. By Distribution Channel

    21.5. Brazil Analgesics Market Analysis

        21.5.1. By Drug Class

        21.5.2. By Indication

        21.5.3. By Route of Administration

        21.5.4. By Distribution Channel

    21.6. Germany Analgesics Market Analysis

        21.6.1. By Drug Class

        21.6.2. By Indication

        21.6.3. By Route of Administration

        21.6.4. By Distribution Channel

    21.7. Italy Analgesics Market Analysis

        21.7.1. By Drug Class

        21.7.2. By Indication

        21.7.3. By Route of Administration

        21.7.4. By Distribution Channel

    21.8. France Analgesics Market Analysis

        21.8.1. By Drug Class

        21.8.2. By Indication

        21.8.3. By Route of Administration

        21.8.4. By Distribution Channel

    21.9. U.K. Analgesics Market Analysis

        21.9.1. By Drug Class

        21.9.2. By Indication

        21.9.3. By Route of Administration

        21.9.4. By Distribution Channel

    21.10. Spain Analgesics Market Analysis

        21.10.1. By Drug Class

        21.10.2. By Indication

        21.10.3. By Route of Administration

        21.10.4. By Distribution Channel

    21.11. BENELUX Analgesics Market Analysis

        21.11.1. By Drug Class

        21.11.2. By Indication

        21.11.3. By Route of Administration

        21.11.4. By Distribution Channel

    21.12. Russia Analgesics Market Analysis

        21.12.1. By Drug Class

        21.12.2. By Indication

        21.12.3. By Route of Administration

        21.12.4. By Distribution Channel

    21.13. China Analgesics Market Analysis

        21.13.1. By Drug Class

        21.13.2. By Indication

        21.13.3. By Route of Administration

        21.13.4. By Distribution Channel

    21.14. Japan Analgesics Market Analysis

        21.14.1. By Drug Class

        21.14.2. By Indication

        21.14.3. By Route of Administration

        21.14.4. By Distribution Channel

    21.15. South Korea Analgesics Market Analysis

        21.15.1. By Drug Class

        21.15.2. By Indication

        21.15.3. By Route of Administration

        21.15.4. By Distribution Channel

    21.16. India Analgesics Market Analysis

        21.16.1. By Drug Class

        21.16.2. By Indication

        21.16.3. By Route of Administration

        21.16.4. By Distribution Channel

    21.17. ASEAN Analgesics Market Analysis

        21.17.1. By Drug Class

        21.17.2. By Indication

        21.17.3. By Route of Administration

        21.17.4. By Distribution Channel

    21.18. Australia Analgesics Market Analysis

        21.18.1. By Drug Class

        21.18.2. By Indication

        21.18.3. By Route of Administration

        21.18.4. By Distribution Channel

    21.19. New Zealand Analgesics Market Analysis

        21.19.1. By Drug Class

        21.19.2. By Indication

        21.19.3. By Route of Administration

        21.19.4. By Distribution Channel

    21.20. GCC Countries Analgesics Market Analysis

        21.20.1. By Drug Class

        21.20.2. By Indication

        21.20.3. By Route of Administration

        21.20.4. By Distribution Channel

    21.21. Turkey Analgesics Market Analysis

        21.21.1. By Drug Class

        21.21.2. By Indication

        21.21.3. By Route of Administration

        21.21.4. By Distribution Channel

    21.22. South Africa Analgesics Market Analysis

        21.22.1. By Drug Class

        21.22.2. By Indication

        21.22.3. By Route of Administration

        21.22.4. By Distribution Channel

22. Market Structure Analysis

    22.1. Market Share Analysis

    22.2. Market Analysis by Tier of Companies 

    22.3. Market Concentration

23. Competition Analysis

    23.1. Competition Dashboard

    23.2. Competition Deep Dive 

        23.2.1. Pfizer Inc.

            23.2.1.1. Overview

            23.2.1.2. Product Offering

            23.2.1.3. Regional Footprint

            23.2.1.4. Strategy Overview

                23.2.1.4.1. Marketing Strategy

                23.2.1.4.2. Product Strategy

                23.2.1.4.3. Channel Strategy

        23.2.2. Sun Pharmaceutical Industries, Inc.

            23.2.2.1. Overview

            23.2.2.2. Product Offering

            23.2.2.3. Regional Footprint

            23.2.2.4. Strategy Overview

                23.2.2.4.1. Marketing Strategy

                23.2.2.4.2. Product Strategy

                23.2.2.4.3. Channel Strategy

        23.2.3. Sanofi SA

            23.2.3.1. Overview

            23.2.3.2. Product Offering

            23.2.3.3. Regional Footprint

            23.2.3.4. Strategy Overview

                23.2.3.4.1. Marketing Strategy

                23.2.3.4.2. Product Strategy

                23.2.3.4.3. Channel Strategy

        23.2.4. AbbVie Inc. (Allergan plc) 

            23.2.4.1. Overview

            23.2.4.2. Product Offering

            23.2.4.3. Regional Footprint

            23.2.4.4. Strategy Overview

                23.2.4.4.1. Marketing Strategy

                23.2.4.4.2. Product Strategy

                23.2.4.4.3. Channel Strategy

        23.2.5.  Teva Pharmaceuticals 

            23.2.5.1. Overview

            23.2.5.2. Product Offering

            23.2.5.3. Regional Footprint

            23.2.5.4. Strategy Overview

                23.2.5.4.1. Marketing Strategy

                23.2.5.4.2. Product Strategy

                23.2.5.4.3. Channel Strategy

        23.2.6. Boehringer Ingelheim International GmbH 

            23.2.6.1. Overview

            23.2.6.2. Product Offering

            23.2.6.3. Regional Footprint

            23.2.6.4. Strategy Overview

                23.2.6.4.1. Marketing Strategy

                23.2.6.4.2. Product Strategy

                23.2.6.4.3. Channel Strategy

        23.2.7. Janssen Pharmaceuticals, Inc. [Johnson & Johnson] 

            23.2.7.1. Overview

            23.2.7.2. Product Offering

            23.2.7.3. Regional Footprint

            23.2.7.4. Strategy Overview

                23.2.7.4.1. Marketing Strategy

                23.2.7.4.2. Product Strategy

                23.2.7.4.3. Channel Strategy

        23.2.8. Endo Pharmaceuticals Inc. 

            23.2.8.1. Overview

            23.2.8.2. Product Offering

            23.2.8.3. Regional Footprint

            23.2.8.4. Strategy Overview

                23.2.8.4.1. Marketing Strategy

                23.2.8.4.2. Product Strategy

                23.2.8.4.3. Channel Strategy

        23.2.9. Purdue Pharmaceuticals L.P. 

            23.2.9.1. Overview

            23.2.9.2. Product Offering

            23.2.9.3. Regional Footprint

            23.2.9.4. Strategy Overview

                23.2.9.4.1. Marketing Strategy

                23.2.9.4.2. Product Strategy

                23.2.9.4.3. Channel Strategy

        23.2.10. Assertio Therapeutics, Inc.

            23.2.10.1. Overview

            23.2.10.2. Product Offering

            23.2.10.3. Regional Footprint

            23.2.10.4. Strategy Overview

                23.2.10.4.1. Marketing Strategy

                23.2.10.4.2. Product Strategy

                23.2.10.4.3. Channel Strategy 

        23.2.11. Mallinckrodt Pharmaceuticals 

            23.2.11.1. Overview

            23.2.11.2. Product Offering

            23.2.11.3. Regional Footprint

            23.2.11.4. Strategy Overview

                23.2.11.4.1. Marketing Strategy

                23.2.11.4.2. Product Strategy

                23.2.11.4.3. Channel Strategy

        23.2.12. Bayer AG 

            23.2.12.1. Overview

            23.2.12.2. Product Offering

            23.2.12.3. Regional Footprint

            23.2.12.4. Strategy Overview

                23.2.12.4.1. Marketing Strategy

                23.2.12.4.2. Product Strategy

                23.2.12.4.3. Channel Strategy

        23.2.13. GlaxoSmithKline plc. 

            23.2.13.1. Overview

            23.2.13.2. Product Offering

            23.2.13.3. Regional Footprint

            23.2.13.4. Strategy Overview

                23.2.13.4.1. Marketing Strategy

                23.2.13.4.2. Product Strategy

                23.2.13.4.3. Channel Strategy

        23.2.14. Bausch Health Companies Inc.

            23.2.14.1. Overview

            23.2.14.2. Product Offering

            23.2.14.3. Regional Footprint

            23.2.14.4. Strategy Overview

                23.2.14.4.1. Marketing Strategy

                23.2.14.4.2. Product Strategy

                23.2.14.4.3. Channel Strategy

        23.2.15. Novartis AG 

            23.2.15.1. Overview

            23.2.15.2. Product Offering

            23.2.15.3. Regional Footprint

            23.2.15.4. Strategy Overview

                23.2.15.4.1. Marketing Strategy

                23.2.15.4.2. Product Strategy

                23.2.15.4.3. Channel Strategy

        23.2.16. Others

            23.2.16.1. Overview

            23.2.16.2. Product Offering

            23.2.16.3. Regional Footprint

            23.2.16.4. Strategy Overview

                23.2.16.4.1. Marketing Strategy

                23.2.16.4.2. Product Strategy

                23.2.16.4.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 02: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 03: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 04: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 05: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 06: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel 

Table 07: Global Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Region

Table 08: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 09: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 10: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 11: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 12: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 13: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 14: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 15: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 16: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 17: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 18: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 19: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 20: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 21: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 22: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 23: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 24: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 25: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 26: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 27: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 28: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 29: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 30: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 31: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 32: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 33: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 34: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 35: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 36: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 37: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Table 38: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Country

Table 39: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Drug Class

Table 40: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Table 41: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Table 42: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01 : Global Opioid Analgesics Market Value (US$ Mn) Forecast, 2021 – 2031

Figure 02 : Global Opioid Analgesics Market Share, By Drug Class (2021)

Figure 03 : Global Opioid Analgesics Market Share, By Region (2021)

Figure 04: Global Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 05: Global Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%) Analysis, 2021-2031

Figure 06: Global Opioid Analgesics Market Absolute $ Opportunity Analysis, 2021-2031

Figure 07: Global Opioid Analgesics Market Analysis By Drug Class–2021 & 2031

Figure 08: Global Opioid Analgesics Market Y-o-Y Growth Projections By Drug Class, 2021-2031

Figure 09: Global Opioid Analgesics Market Attractiveness, By Drug Class

Figure 10: Global Opioid Analgesics Market Analysis By Indication–2021 & 2031

Figure 11: Global Opioid Analgesics Market Y-o-Y Growth Projections By Indication, 2021-2031

Figure 12: Global Opioid Analgesics Market Attractiveness, By Indication

Figure 13: Global Opioid Analgesics Market Analysis By Route of Administration – 2021 & 2031

Figure 14: Global Opioid Analgesics Market Y-o-Y Growth Projections By Route of Administration, 2021-2031

Figure 15: Global Opioid Analgesics Market Attractiveness, By Route of Administration 

Figure 16: Global Opioid Analgesics Market Analysis By Distribution Channel–2021 & 2031

Figure 17: Global Opioid Analgesics Market Y-o-Y Growth Projections By Distribution Channel, 2021-2031

Figure 18: Global Opioid Analgesics Market Attractiveness, By Distribution Channel 

Figure 19: Global Opioid Analgesics Market Analysis by Region–2021 & 2031

Figure 20: Global Opioid Analgesics Market Y-o-Y Growth Projections by Region, 2021-2031

Figure 21: Global Opioid Analgesics Market Attractiveness, By Region

Figure 22: North America Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 23: North America Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 24: North America Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 25: North America Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 26: North America Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 27: North America Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 28: North America Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 29: North America Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 30: North America Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 31: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 32: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 33: North America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 34: Latin America Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 35: Latin America Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 36: Latin America Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 37: Latin America Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 38: Latin America Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 39: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 40: Latin America Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 41: Latin America Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 42: Latin America Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 43: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 44: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 45: Latin America Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 46: Europe Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 47: Europe Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 48: Europe Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 49: Europe Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 50: Europe Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 51: Europe Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 52: Europe Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 53: Europe Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 54: Europe Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 55: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 56: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 57: Europe Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 58: South Asia Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 59: South Asia Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 60: South Asia Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 61: South Asia Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 62: South Asia Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 63: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 64: South Asia Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 65: South Asia Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 66: South Asia Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 67: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 68: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 69: South Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 70: East Asia Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 71: East Asia Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 72: East Asia Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 73: East Asia Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 74: East Asia Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 75: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 76: East Asia Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 77: East Asia Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 78: East Asia Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 79: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 80: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 81: East Asia Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 82: Oceania Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 83: Oceania Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 84: Oceania Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 85: Oceania Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 86: Oceania Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 87: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 88: Oceania Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 89: Oceania Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 90: Oceania Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 91: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 92: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 93: Oceania Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 94: MEA Opioid Analgesics Market Share, By Drug Class, 2021 (E)

Figure 95: MEA Opioid Analgesics Market Share, By Indication, 2021 (E)

Figure 96: MEA Opioid Analgesics Market Share, By Route of Administration, 2021 (E)

Figure 97: MEA Opioid Analgesics Market Share, By Distribution Channel, 2021 (E)

Figure 98: MEA Opioid Analgesics Market Share, By Country, 2021 (E)

Figure 99: MEA Opioid Analgesics Market Size (US$ Mn) Analysis, 2016-2020

Figure 100: MEA Opioid Analgesics Market Size (US$ Mn) & Y-o-Y Growth (%), 2021-2031

Figure 101: MEA Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Country

Figure 102: MEA Opioid Analgesics Market Attractiveness Analysis 2021-2031 By Drug Class

Figure 103: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Indication

Figure 104: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Route of Administration

Figure 105: MEA Opioid Analgesics Market Size (US$ Mn) Analysis 2016-2020 and Forecast 2021-2031, By Distribution Channel

Figure 106: Global Opioid Analgesics Market Value Proportion Analysis, By Emerging Countries, 2020

Figure 107: Opioid Analgesics Market, Global Vs. Country Growth Y-o-Y (%) Comparison, 2021-2031

Figure 108: U.S. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 109: U.S. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 110: U.S. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 111: U.S. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 112: Canada Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 113: Canada Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 114: Canada. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 115: Canada. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 116: Brazil. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 117: Brazil. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 118: Brazil. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 119: Brazil. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 120: Mexico. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 121: Mexico. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 122: Mexico. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 123: Mexico. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 124: UK. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 125: UK. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 126: UK. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 127: UK. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 128: Germany. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 129: Germany. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 130: Germany. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 131: Germany. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 132: Italy. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 133: Italy. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 134: Italy. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 135: Italy. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 136: France. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 137: France. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 138: France. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 139: France. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 140: Spain. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 141: Spain. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 142: Spain. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 143: Spain. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 144: Russia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 145: Russia. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 146: Russia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 147: Russia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 148: BENELUX Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 149: BENELUX Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 150: BENELUX Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 151: BENELUX Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 152: China. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 153: China. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 154: China. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 155: China. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 156: Japan. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 157: Japan. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 158: Japan. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 159: Japan. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 160: South Korea. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 161: South Korea. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 162: South Korea. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 163: South Korea. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 164: India. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 165: India. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 166: India. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 167: India. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 168: Thailand. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 169: Thailand. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 170: Thailand. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 171: Thailand. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 172: Indonesia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 173: Indonesia. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 174: Indonesia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 175: Indonesia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 176: Malaysia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 177: Malaysia. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 178: Malaysia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 179: Malaysia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 180: Australia. Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 181: Australia. Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 182: Australia. Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 183: Australia. Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 184: New Zealand Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 185: New Zealand Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 186: New Zealand Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 187: New Zealand Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 188: Turkey Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 189: Turkey Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 190: Turkey Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 191: Turkey Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 192: GCC Countries Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 193: GCC Countries Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 194: GCC Countries Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 195: GCC Countries Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Figure 196: South Africa Opioid Analgesics Market Share Analysis (%) By Drug Class, 2021 & 2031

Figure 197: South Africa Opioid Analgesics Market Share Analysis (%) By Indication, 2021 & 2031

Figure 198: South Africa Opioid Analgesics Market Share Analysis (%) By Route of Administration, 2021 & 2031

Figure 199: South Africa Opioid Analgesics Market Share Analysis (%) By Distribution Channel, 2021 & 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Over-the-Counter Pain Medication Market

Published : March 2022

Healthcare

Oxycodone Market

Published : June 2021

Healthcare

Analgesics Market

Published : December 2021

Google translate

Opioid Analgesics Market